The first year
Type IIB von Willebrand disease
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No
PAI-1 and vasculopathy
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)
What the structure of angiostatin may tell us about its mechanism of action
Folate, homocysteine levels, methylenetetrahydrofolate reductase (MTHFR) 677C → T variant, and the risk of myocardial infarction in young women
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation
A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
Enhanced leukocyte–platelet cross-talk in Type 1 diabetes mellitus
Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia
Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation
Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits
Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells
Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice
G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation
Factor XII-dependent increases in thrombin activity induce carboxypeptidase-mediated attenuation of pharmacological fibrinolysis
Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor
Different effects of abciximab and cytochalasin D on clot strength in thrombelastography
Differential response of platelets to chemokines
von Willebrand factor binding to platelet glycoprotein Ib-IX-V stimulates the assembly of an α-actinin-based signaling complex
Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF–GPIb-dependent process, defective in Bernard–Soulier syndrome
Activation of integrin αIIbβ3 in the glycoprotein Ib-high population of a megakaryocytic cell line, CMK, by inside-out signaling
The discovery of factor X
The discovery of factor X
The discovery of factor X
The discovery of factor X
Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia
A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia
An informed consent form for treatment with oral anticoagulants
The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation
Soluble thrombomodulin in patients with established atherosclerosis
Psychological factors and cardiovascular disease
Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2
The factor VIII gene intron 1 inversion mutation